Document is current
Any future updates will be listed below
-
Authors
Gagnon, Eloi https://orcid.org/0000-0002-7483-1371
Mitchell, Patricia L. https://orcid.org/0000-0002-0773-1047
Manikpurage, Hasanga D. https://orcid.org/0000-0002-2365-6956
Abner, Erik https://orcid.org/0000-0002-6529-3161
Taba, Nele
Esko, Tõnu https://orcid.org/0000-0003-1982-6569
Ghodsian, Nooshin https://orcid.org/0000-0003-2042-6001
Thériault, Sébastien https://orcid.org/0000-0003-1893-8307
Mathieu, Patrick
Arsenault, Benoit J. https://orcid.org/0000-0003-2240-8456
-
Funding
Funding for this research was provided by:
Fonds de Recherche du Québec - Santé
Canadian Institutes of Health Research
- License Information
-
More Information
Article History
Received: 31 May 2022
Accepted: 30 November 2022
First Online: 30 January 2023
Declarations
:
: All data used in this study are in the public domain. All participants provided informed consent and study protocols were approved by their respective local ethical committees <sup>29–32,64,67,86–94,94–97</sup>. This project was approved by the Institutional Review Board of the Quebec Heart and Lung Institute.
: BJA is a consultant for Novartis and Silence Therapeutics and has received research contracts from Pfizer, Ionis Pharmaceuticals and Silence Therapeutics.
